Keystone Nano
35+ years in pharmaceutical development; 25 INDs; 4 product approvals; founded and sold two biopharma companies (Principia, BioRexis) with exits exceeding $500 million; Raised $75 million as CEO of PhaseBIO; took Innovate Biopharmaceuticals 4 public; director of R&D at Aventis (now Sanofi), senior product development scientist at Biogen (7th
employee).
This person is not in any teams
This person is not in any offices
Keystone Nano
KN is developing products to treat cancer with unique, effective, targeted nano therapies and is starting clinical testing in 2016.